National Pregnancy Registry for Psychiatric Medications
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-45
SponsorMassachusetts General Hospital
About this trial
The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.
Eligibility criteria
Qualifiers
Pregnant women
Age 18-45
Subjects will be willing to participate over the phone
Subjects will be able to provide informed consent
Disqualifiers
Women who have completed their pregnancy
Women who are planning to become pregnant
Women who are not taking any psychiatric medications and/or have no history of psychiatric illness
Trial design
Treatments tested in this trial
- Not listed
Trial groups
5,000 Participants
are grouped into 5 trial groupsSponsors and collaborators
Massachusetts General Hospital
Lead sponsor
Alkermes, Inc.
Collaborator
Eisai Inc.
Collaborator
Otsuka America Pharmaceutical
Collaborator
Supernus Pharmaceuticals, Inc.
Collaborator
Sage Therapeutics
Collaborator
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov